In one PSMA-negative PCa case, the authors observed a high-intermediate [68Ga]Ga-DOTA-FAPi-04 uptake; however, in three NEPCa cases, the authors reported low uptake (SUVmax < 6), which is different from the findings of Vlachostergios et al., who reported high mRNA FAP expression levels in 21 patients with NEPCa who received previous treatment with taxanes and abiraterone or enzalutamide [17]. This evidence concerns the gene FAP and posterior cortical atrophy.